PU.1通过抑制FLT3促进类风湿关节炎的发展
该研究在类风湿关节炎(RA)患者滑膜中检测PU.1与FLT3表达,利用CAIA和CIA小鼠模型及体外巨噬细胞与成纤维样滑膜细胞实验,发现PU.1直接结合FLT3启动子抑制其转录,PU.1抑制剂DB2313在两种关节炎模型中减轻关节炎发展。
要点
- RA患者滑膜中PU.1表达升高,而FLT3及p-FLT3表达降低。
- PU.1促进巨噬细胞和FLS的过度活化与炎症状态,FLT3作用相反。
- PU.1抑制剂DB2313在CAIA和CIA模型中减轻关节炎发展。
核心结论
- 结果支持PU.1在RA中的作用,并可能通过直接抑制FLT3产生治疗意义,作者认为靶向PU.1可能是RA的潜在治疗途径。
研究设计与样本
- 研究检测RA患者滑膜中PU.1与FLT3的表达和定位,使用PU.1敲低(UREΔ)和FLT3激活(FLT3-ITD)小鼠建立胶原抗体诱导关节炎(CAIA),并在体外用siRNA研究PU.1和FLT3对原代巨噬细胞和成纤维样滑膜细胞(FLS)的作用。
- 机制研究采用荧光素酶报告基因试验、蛋白质印迹、FACS和免疫组化,并用PU.1小分子抑制剂DB2313在CAIA和CIA两种体内模型中观察治疗效应。
主要发现
- 与骨关节炎患者和正常对照相比,RA患者滑膜中PU.1表达被诱导升高。
- RA中FLT3和p-FLT3与PU.1呈现相反的 expresión 模式。
- CAIA模型显示PU.1是关节炎发展的激活因子,而FLT3是抑制因子。
- 体外实验与体内结果一致:PU.1促进巨噬细胞和FLS的过度活化与炎症状态,FLT3作用相反。
- PU.1通过直接结合FLT3启动子区域抑制FLT3转录,PU.1抑制剂DB2313在CAIA和CIA模型中明显减轻关节炎发展。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To uncover the function and underlying mechanism of an essential transcriptional factor, PU.1, in the development of rheumatoid arthritis (RA). METHODS: The expression and localisation of PU.1 and its potential target, FMS-like tyrosine kinase 3 (FLT3), in the synovium of patients with RA were determined by western blot and immunohistochemical (IHC) staining. UREΔ (with PU.1 knockdown) and FLT3-ITD (with FLT3 activation) mice were used to establish collagen antibody-induced arthritis (CAIA). For the in vitro study, the effects of PU.1 and FLT3 on primary macrophages and fibroblast-like synoviocytes (FLS) were investigated using siRNAs. Mechanistically, luciferase reporter assays, western blotting, FACS and IHC were conducted to show the direct regulation of PU.1 on the transcription of FLT3 in macrophages and FLS. Finally, a small molecular inhibitor of PU.1, DB2313, was used to further illustrate the therapeutic effects of DB2313 on arthritis using two in vivo models, CAIA and collagen-induced arthritis (CIA). RESULTS: The expression of PU.1 was induced in the synovium of patients with RA when compared with that in osteoarthritis patients and normal controls. FLT3 and p-FLT3 showed opposite expression patterns compared with PU.1 in RA. The CAIA model showed that PU.1 was an activator, whereas FLT3 was a repressor, of the development of arthritis in vivo. Moreover, results from in vitro assays were consistent with the in vivo results: PU.1 promoted hyperactivation and inflammatory status of macrophages and FLS, whereas FLT3 had the opposite effects. In addition, PU.1 inhibited the transcription of FLT3 by directly binding to its promoter region. The PU.1 inhibitor DB2313 clearly alleviated the effects on arthritis development in the CAIA and CIA models. CONCLUSIONS: These results support the role of PU.1 in RA and may have therapeutic implications by directly repressing FLT3. Therefore, targeting PU.1 might be a potential therapeutic approach for RA.
引用
- Tu J, Chen W, Fang Y, et al. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes. Ann Rheum Dis. 2022. PMID: 36198439. doi:10.1136/ard-2022-222708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。